Page Banner

United States Department of Agriculture

Agricultural Research Service

Related Topics

Research Project: Development of Novel Foot-and-Mouth Disease Virus with Multiple Mutations for Evaluation As Live Attenuated Diva Vaccine Candidate

Location: Foreign Animal Disease Research

Project Number: 8064-32000-057-48
Project Type: Trust

Start Date: Dec 01, 2012
End Date: Nov 30, 2014

Objective:
This research project seeks to improve current strategies to generate Foot-and-Mouth Disease Virus (FMDV) containing specific attenuating factors and antigenic markers and evaluate their potential as vaccine candidates. We have previously developed mutations in the leader protein of FMDV which attenuated the virus for use as a vaccine candidate. There is a need to identify and introduce mutations located in other nonstructural proteins which will provide addititional attenuating factors, avoiding reversion to virulence and thereby increasing stability, to further improve efforts for vaccine development. The specific objectives are: 1. Test the virulence in swine of A24 FMDV L sap. 2. Construct and characterize in vitro, FMDV strains with mutations in the L sap in combination with deletions/mutations in the 3B coding region. 3. Test the virulence in swine of mutant FMDV L sap 3B mut strains.

Approach:
1. Test the virulence of FMDV L sap mutant within the context of A24 which was derived from an infectious cDNA clone of FMDV field strain A 24Cruzeiro. In vivo studies will be conducted in swine utilizing different doses of A24-FMDV Lsap mutant. Clinical signs will be measured. 2. Mutant FMDV will be constructed by deleting or substituting conserved residues in the 3B region of the infectious clone of A24-FMDVL sap. Plasmids will be transcribed and resulting products analyzed. The full-length transcripts transcripts will be introduced into baby hamster kidney (BHK)-21 cells to recover infectious virus which will be characterized for in vitro activity. Mutant viruses (A24-FMDVLsap3Bmut) with an attenuated phenotype will be selected for further characterization in vivo. 3. The virulence of the mutants derived (above) will be studied in vivo in swine. Clinical signs and induction of adaptive immunity will be monitored.

Last Modified: 12/20/2014
Footer Content Back to Top of Page